Facebook
Twitter
Telegram
Report an ErrorTheravance Biopharma Balance Sheet 2011-2024 | TBPH
Annual Balance Sheet Theravance Biopharma
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
-246 M | 527 M | - | 397 M | 76.3 M | 135 M | -122 M | -113 M | -89.2 M | - | - | - | |
Long Term Debt |
- | 45.4 M | 616 M | - | 445 M | 454 M | 224 M | 223 M | - | - | - | - | - |
Long Term Debt Current |
3.92 M | 6.75 M | 503 K | 9.87 M | 7.76 M | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | 521 M | 513 M | 264 M | 240 M | 7.58 M | 6.73 M | 5.3 M | - | - |
Total Current Liabilities |
24.8 M | 28.7 M | 58.6 M | 124 M | 112 M | 98.6 M | 62.6 M | 49.3 M | 49.5 M | 41.3 M | - | - | - |
Total Liabilities |
- | - | - | - | 633 M | 612 M | 326 M | 289 M | 57.1 M | 48 M | 42.2 M | - | - |
Deferred Revenue |
- | - | 98 K | 11.5 M | 31.6 M | 43.4 M | 125 K | 152 K | 144 K | 89 K | - | - | - |
Retained Earnings |
-909 M | -854 M | -1.73 B | - | -1.25 B | -1.01 B | -798 M | -512 M | -322 M | -139 M | - | - | - |
Total Assets |
382 M | 607 M | 375 M | 469 M | 409 M | 560 M | 441 M | 639 M | 300 M | 338 M | 25.2 M | - | - |
Cash and Cash Equivalents |
39.5 M | 298 M | 90 M | 81.5 M | 58.1 M | 378 M | 89 M | 345 M | 113 M | 89.2 M | - | - | - |
Book Value |
382 M | 607 M | 375 M | 469 M | -224 M | -51.6 M | 115 M | 350 M | 243 M | 290 M | -17 M | - | - |
Total Shareholders Equity |
213 M | 442 M | -339 M | -304 M | -224 M | -51.6 M | 115 M | 350 M | 243 M | 290 M | -17 M | -6.99 M | - |
All numbers in USD currency
Quarterly Balance Sheet Theravance Biopharma
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
41.1 M | 42.5 M | 43.8 M | 45.4 M | 51.4 M | 625 M | 621 M | 52.7 M | 616 M | 610 M | 614 M | 619 M | 47.2 M | 47.2 M | 47.2 M | 455 M | 47.7 M | 47.7 M | 47.7 M | 454 M | - | - | - | 224 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
24 K | 24 K | 24 K | 24 K | 24 K | 24 K | 98 K | 98 K | 2.9 M | 5.69 M | 7.66 M | 11.5 M | 11.5 M | 11.5 M | 11.5 M | 31.6 M | 31.6 M | 31.6 M | 31.6 M | 43.4 M | 43.4 M | 43.4 M | 43.4 M | 125 K | 134 K | 142 K | 142 K | 152 K | 152 K | 152 K | 152 K | 144 K | 144 K | 144 K | 144 K | 89 K | 89 K | 89 K | 89 K | 8.21 M | 8.21 M | 8.21 M | 8.21 M | - | - | - | - | - | - | - | - |
Retained Earnings |
-901 M | -892 M | -876 M | -854 M | -844 M | -1.76 B | -1.75 B | -1.73 B | -1.69 B | -1.66 B | -1.61 B | -1.53 B | -1.53 B | -1.53 B | -1.53 B | -1.25 B | -1.25 B | -1.25 B | -1.25 B | -1.01 B | -1.01 B | -1.01 B | -1.01 B | -798 M | -798 M | -798 M | -798 M | -512 M | -512 M | -512 M | -512 M | -322 M | -322 M | -322 M | -322 M | -139 M | -139 M | -139 M | -139 M | - | - | - | - | - | - | - | - | - | - | - | - |
Total Assets |
414 M | 447 M | 539 M | 607 M | 763 M | 361 M | 355 M | 375 M | 403 M | 429 M | 375 M | 469 M | 469 M | 469 M | 469 M | 409 M | 409 M | 409 M | 409 M | 560 M | 560 M | 560 M | 560 M | 441 M | 441 M | 441 M | 441 M | 639 M | 639 M | 639 M | 639 M | 300 M | 300 M | 300 M | 300 M | 338 M | 338 M | 338 M | 338 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
71.7 M | 106 M | 188 M | 298 M | 419 M | 87.3 M | 94.4 M | 90 M | 121 M | 205 M | 114 M | 82.3 M | 81.5 M | 81.5 M | 81.5 M | 58.1 M | 58.1 M | 58.1 M | 58.1 M | 378 M | 378 M | 378 M | 378 M | 89 M | 89 M | 89 M | 89 M | 345 M | 345 M | 345 M | 345 M | 113 M | 113 M | 113 M | 113 M | 89.2 M | 89.2 M | 89.2 M | 89.2 M | - | - | - | - | - | - | - | - | - | - | - | - |
Book Value |
414 M | 447 M | 539 M | 607 M | 763 M | 361 M | 355 M | 375 M | 403 M | 429 M | 375 M | 469 M | 469 M | 469 M | 469 M | 409 M | 409 M | 409 M | 409 M | 560 M | 560 M | 560 M | 560 M | 441 M | 441 M | 441 M | 441 M | 639 M | 639 M | 639 M | 639 M | 300 M | 300 M | 300 M | 300 M | 338 M | 338 M | 338 M | 338 M | 25.2 M | 25.2 M | 25.2 M | 25.2 M | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
246 M | 280 M | 371 M | 442 M | 481 M | -350 M | -351 M | -339 M | -324 M | -300 M | -373 M | -304 M | -304 M | -304 M | -304 M | -224 M | -224 M | -224 M | -224 M | -51.6 M | -51.6 M | -51.6 M | -51.6 M | 115 M | 115 M | 115 M | 115 M | 350 M | 350 M | 350 M | 350 M | 243 M | 243 M | 243 M | 243 M | 290 M | 290 M | 290 M | 290 M | -17 M | -17 M | -17 M | -17 M | -6.99 M | - | - | - | -141 M | - | - | - |
All numbers in USD currency